A5049217973- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Gastric Cancer Management and Outcomes
- Cancer-related Molecular Pathways
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Epigenetics and DNA Methylation
- Amino Acid Enzymes and Metabolism
- Immune cells in cancer
- Metastasis and carcinoma case studies
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- RNA Research and Splicing
- Acute Lymphoblastic Leukemia research
- Cancer, Lipids, and Metabolism
- Gastrointestinal Tumor Research and Treatment
- Phagocytosis and Immune Regulation
- Liver Disease Diagnosis and Treatment
- Vascular Anomalies and Treatments
- Vagus Nerve Stimulation Research
- Anesthesia and Pain Management
- Opioid Use Disorder Treatment
- Layered Double Hydroxides Synthesis and Applications
Peter MacCallum Cancer Centre
2013-2025
Austin Health
2018-2024
Northern Health
2023
The University of Melbourne
2020-2022
Victorian Comprehensive Cancer Centre
2019
Monash Health
2016
Monash Institute of Medical Research
2013
Monash University
2013
Monash Medical Centre
2012
The mechanism of action eprenetapopt (APR-246, PRIMA-1MET) as an anticancer agent remains unresolved, although the clinical development focuses on its reported a mutant-p53 reactivator. Using unbiased approaches, this study demonstrates that depletes cellular antioxidant glutathione levels by increasing turnover, triggering nonapoptotic, iron-dependent form cell death known ferroptosis. Deficiency in genes responsible for supplying cancer cells with substrates de novo synthesis (SLC7A11,...
Abstract APR-246 (eprenetapopt) is in clinical development with a focus on hematologic malignancies and promoted as mutant-p53 reactivation therapy. Currently, the detection of at least one TP53 mutation an inclusion criterion for patient selection into most trials. Preliminary results from our phase Ib/II trial investigating combined doublet chemotherapy [cisplatin 5-fluorouracil (5-FU)] metastatic esophageal cancer, together previous preclinical studies, indicate that status alone may not...
Brief but severe asphyxia in late gestation or at the time of birth may lead to neonatal hypoxic ischemic encephalopathy and is associated with long-term neurodevelopmental impairment. We undertook this study examine consequences transient utero fetal sheep, on newborn lamb after birth. Surgery was undertaken 125 days for implantation catheters placement a silastic cuff around umbilical cord. At 132 (0.89 term), inflated induce cord occlusion (UCO), sham (control). Fetal arterial blood...
Objective: To explore the clinical utility of circulating tumor DNA (ctDNA) in esophageal adenocarcinoma (EAC) by developing a cost-effective and rapid technique utilising targeted amplicon sequencing. Summary background data: Emerging evidence suggests that levels ctDNA blood can be used to monitor treatment response detection disease recurrence various cancer types. Current staging modalities for EAC such as computerised tomography chest/abdomen/pelvis (CT) positron emission (PET) do not...
Background Previous studies have suggested that patients with occult peritoneal metastases not seen on preoperative imaging poor prognosis. In this study, we aim to evaluate the utility and impact of staging laparoscopy cytology in gastric adenocarcinoma. Methods A retrospective analysis adenocarcinoma managed at two major metropolitan hospitals Melbourne, Australia, between January 1999 July 2010 was undertaken. The main outcome measures were number whom and/or changed treatment intent,...
The Esophagectomy Complications Consensus Group (ECCG) and the Dutch Upper Gastrointestinal Cancer Audit (DUCA) have set standards in reporting outcomes after oesophagectomy. Reporting from selected high-volume centres or centralized national cancer programmes may not, however, be reflective of true global prevalence complications. This study aimed to compare complication rates oesophagectomy these existing sources with those an unselected international cohort Oesophago-Gastric Anastomosis...
Summary Esophageal Cancer is the seventh commonest cancer worldwide with poor overall survival. Significant morbidity related to open esophagectomy has driven practice toward hybrid, totally minimally invasive and robotic procedures. With increase in approaches, it been suggested that there might be an increased incidence of subsequent para-conduit diaphragmatic hernia. To assess incidence, modifiable risk factors association operative approach this emerging complication, we evaluated...
In esophageal cancer (EC), there is a paucity of knowledge regarding the interplay between tumor immune microenvironment and response to neoadjuvant treatment and, therefore, which factors may influence outcomes. Thus, our goal was investigate changes in with EC by assessing expression related genes their association prognosis.
Abstract Esophageal adenocarcinoma (EAC) is a cancer of high mutation burden with negligible recurrent and druggable driver genes and, therefore, paucity options for targeted therapy. Mutation or loss the tumor suppressor gene SMAD4 occurs in up to 20% EAC cases, we have previously shown that sufficient promote tumorigenesis an vivo xenograft model. The present study aimed delineate role identify synthetic lethal interactions SMAD4-deficient cancers as novel approach treating EAC. Our...
Abstract This abstract is being presented as a short talk in the scientific program. A full printed Proffered Abstracts section (PR007) of Conference Program/Proceedings. Citation Format: Julia V Milne, Ebtihal Mustafa, Kenji Fujihara, Eric Kusnadi, Anna Trigos, Niko Thio, Maree Pechlivanis, Carlos Cabalag, Twishi Gulati, Kaylene Simpson, Cuong Duong, Luc Furic, Wayne Phillips, Nicholas Clemons. Delineating functional drivers esophageal adenocarcinoma to identify synthetic lethal...
Abstract Application of molecular targeted therapies for esophageal adenocarcinoma (EAC) has been limited by a lack druggable oncogenic drivers. We propose that synthetic lethal interactions may provide new opportunities in EAC. have taken an integrated multi-omics approach incorporating Perturb-Seq (CRISPR editing combined with single cell RNA sequencing) and vivo tumorigenesis assays to perform high-throughput characterisation >70 high-confidence EAC driver genes, genome-wide...
ABSTRACT Purpose APR-246 (Eprenetapopt) is in clinical development with a focus on haematological malignancies and marketed as mutant-p53 reactivation therapy. Currently, the detection of at least one TP53 mutation an inclusion criterion for patient selection into most trials. Preliminary results from our phase Ib/II trial investigating combined combination chemotherapy (cisplatin 5-Fluorouracil) metastatic oesophageal cancer, together previous pre-clinical studies, indicate that status...
Abstract De Garengeot hernia is a rare type of femoral in which the appendix contained within hernial sac. Due to its rarity, there limited evidence regarding optimal surgical approach. Twenty-five reports repair using laparoscopic transabdominal preperitoneal (TAPP) technique have been identified; however, lack consensus pertaining preoperative diagnosis and whether concurrent appendicectomy performed. In addition, debate over use covering mesh. A 34-year-old woman presented with 5-week...